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2UIS-ESSLei-IPLeiria, Campus 2, Morro do Lena, Apartado 4137, 2411-901 Leiria, Portugal
3Faculty of Health Sciences, Beira Interior University, Avenue Infante D. Henrique, 6200-506 Covilhã, Portugal
Correspondence should be addressed to Ana Glória Fonseca; ana.fonseca@fcm.unl.pt
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Background. Although eradicated in Portugal, malaria keeps taking its toll on travelers and migrants from endemic countries.
Disease notification is mandatory but is compromised by underreporting.Methods. A retrospective study on malaria hospitaliza-
tions for 10 consecutive years (2000–2009) was conducted. Data on hospitalizations and notifications were obtained from Central
Administration of Health System and Health Protection Agency, respectively. For data selection ICD-9 CM and ICD-10 were used:
codes 084∗, 647.4, and B50–B54. Variables were gender, age, agent and origin of infection, length of stay (LOS), lethality, and
comorbidities. Analysis included description, hypothesis testing, and regression. Results. There were 2003 malaria hospitalizations
and 480 notified hospitalized cases, mainly in young male adults. P. falciparum was the main agent of infection acquired mainly
in sub-Saharan Africa. Lethality was 1.95% and mean LOS was 8.09 days. Older age entailed longer LOS and increased lethality.
Discussion. From 2000 to 2009, there were 2003 malaria hospitalizations with decreasing annual incidence, these numbers being
remarkably higher than those notified. The national database of diagnosis related groups, reflecting hospitalizations on NHS
hospitals, may be an unexplored complementary source for better estimates on imported malaria.
1. Introduction
Outside endemic regions, malaria may occur in travellers
that have recently been to or visited endemic regions or in
individuals from endemic countries recently arrived at or
visiting nonendemic regions. Imported malaria is therefore
defined as “an infection that was acquired in an endemic area
by an individual (either a tourist or indigenous native) but
diagnosed in a nonendemic country after development of the
clinical disease” [1].
The increase in international travel and climate changes
are considered important causes for the emergence of
imported malaria. International travel to malarial zones is
estimated at 80–90 million travellers annually and results in
an estimated 30000 annual imported malaria cases world-
wide [2, 3].
Since the year 2000 and contrary to the trend in the
preceding years, there has been a progressive and steady
decrease in the annual incidence of imported malaria that
varied from 15303 reported cases in the World Health Orga-
nization (WHO) European Region in 2000 to 5712 in 2009
[4]. Those promptly diagnosed and treated generally have a
full recovery, making imported malaria an avoidable cause
of death that nevertheless still accounts for a considerable
preventable burden of morbidity and mortality every year in
nonendemic countries.
WHO declared autochthonous malaria eradicated in
Portugal in 1973 [5]. However, due to increasing international
travel and travel related to extensive international cultural
and commercial relations, malaria keeps taking its toll on
travelers and migrants to and from endemic countries.
Disease surveillance consists of a physician based passive case
detection system liable to underreporting. National data on
importedmalaria are scarce or nonexistent, the available data
being based on sporadic single hospital based or regional
based case series and case reports [5–9].
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Complementing notification data may allow for better
malaria burden estimates. Imported hospitalized malaria
cases from 2000 to 2009 were analysed at national level,
using Portugal’s Diagnosis Related Groups (DRG) informa-
tion system from National Health Services (NHS) hospital
episodes statistics and Statutory Notification information
system. Frequency of occurrence, hospital length of stay,
lethality, plasmodium species, and origin of infection were
considered. Secondly, the influence of demographic factors
and comorbidities on in-hospital length of stay and lethality
were analyzed.
2. Methods
A retrospective study was conducted, using Portuguese
National Diagnosis Related Groups (DRG) database, result-
ing from the NHS hospital episodes statistics, and the
National Statutory Notifiable Disease Surveillance database,
resulting from disease notification, provided by the Central
Administration of Health System (ACSS) and the Health
Protection Agency (HPA), respectively. The data were made
anonymous for analysis.
In the DRG database each record corresponds to a
National Health Service (NHS) hospital discharge episode
(hospitalization). The Diagnostic Related Groups (DRG)
were developed as an inpatient classification system that
determines the payment allocated to the hospital [10]. It
provides a complete record of all hospitalizations and is
not compromised by the limitations of existent surveillance
systems, such as under diagnosis or deficiencies in reporting.
Within DRGs the 9th International Classification Disease
Clinical Modification (ICD-9 CM) is used to classify all
diagnosis assigned by the physician at discharge. Malaria
diagnosis implies laboratorial microscopic parasite detec-
tion and/or antigen parasite detection test for Plasmodium
falciparum and nonfalciparum infections. Molecular PCR
technology is not widely available but is possible in some
institutions, mainly those involved in research.
Malaria surveillance, on the other hand, is a passive
mandatory physician based case detection system in Portugal
resulting in the National StatutoryNotifiable Disease Surveil-
lance database [11]. A standardised paper notification form,
equal to all notifiable diseases, is used. During the period
of study only confirmed cases were notified. There is no
laboratory based notification system. In the National Statu-
tory Notifiable Disease Surveillance database each record
corresponds to a case of disease. The 10th International
Classification Disease (ICD-10) is used to classify diagnosis.
The study population was selected using ICD-9 CM,
codes 084 (malaria) [namely 084.0 (Plasmodium falciparum),
084.1 (Plasmodium vivax), 084.2 (Plasmodium malariae),
084.3 (Plasmodium ovale), 084.5 (mixed malaria), 084.6
(malaria unspecified), and 084.9 (pernicious complication)]
and 647.4 (malaria in the mother classifiable elsewhere,
but complicating pregnancy, childbirth, or the puerperium),
for the DRG database and 10th International Classifica-
tion Disease (ICD-10), codes B50 (Plasmodium falciparum),
B51 (Plasmodium vivax), B52 (Plasmodium malariae), B53.0
(Plasmodium ovale), and B54 (malaria unspecified), for the
National Statutory Notifiable Disease Surveillance database.
Data on malaria cases is nationwide and covers a 10-
consecutive-year study period (2000–2009). Variables from
de DRG database included gender, age, year of hospitaliza-
tion, month of hospitalization, district of patient’s residence,
in-hospital length of stay (LOS), and lethality. Variables
from the statutory notification database included year of
notification, agent and origin of infection, and lethality.
Certain characteristics, such as nationality and whether they
are travelers, immigrants, expatriates, or visiting friends and
relatives (VFRs), treatment schedule, chemoprophylaxis use,
and duration of travel in endemic countries, could not be
retrieved from the databases because these items are not
systematically collected.
In the DRG database, potential factors influencing LOS
or death were defined: (a) age > 64 years; (b) gender; (c)
malaria related to pregnancy (ICD-9 code 0647.4); (d) HIV
infection (ICD-9 code 042); (e) other infections excluding
malaria (ICD-9 codes 001–009, 011–018, 020–027, 030–040,
042, 060–066, 070, 071, 082, 083, 085, 086, 091–095, 098, 100,
120–129, and 130); (f) pneumonia (ICD-9 codes 480–486); (g)
respiratory failure (ICD-9 codes 518.81–518.84); (h) chronic
obstructive pulmonary disease (ICD-9 codes 490–496); (i)
diabetes mellitus (ICD-9 code 250); (j) arterial hypertension
(ICD-9 codes 401–405); (k) renal failure (ICD-9 codes 584,
585, 586, 403, and 404); (l) anemia (ICD-9 codes 280–285);
(m) thrombocytopenia (ICD-9 codes 287.4-287.5).
The demographic characteristics of the patients were
summarised using mean and standard deviation (SD) and
medians and interquartile range (IQR) for continuous data
and using proportions for categorical data.Hypothesis testing
was used to compare groups: 𝑡-tests and ANOVA, assuming
normal distribution for continuous data; chi-square test or
Fisher exact test (if the expected values were too small) for
categorical data. Linear regression model was used to study
the length of stay and logistic regression model used to study
the effect on lethality. Due to the skewed length of stay data,
a log transformation was carried out to normalise the data
before multivariate analysis; this procedure is usual for such
data [12, 13]. Although gender and age are not statistically
significant at the 5% level, they were retained in the model
in order to control for possible confounding. Covariates
controlled in multivariate analysis were the potential factors
defined before. The effect sizes from the multivariate analysis
are reported as relative ratios (exponential of the regression
coefficient of the log transformed data) for the in-hospital
length of stay and as odds ratio (OR) for lethality. Confidence
intervals are given at 95% and 𝑃 values less than 0.05
are statistically significant, although the multivariate final
models include covariates with 10% significance level in the
univariate analysis. Data were analysed using R software,
namely, glm library.
3. Results
Table 1 summarizes the general descriptive demographic and
epidemiological characteristics, considering hospitalizations
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Figure 1: Imported malaria hospitalizations and deaths (NHS
DRG database) and notifications of hospitalized cases and deaths
(Statutory Notifiable Disease database) in Portugal 2000–2009.
and notifications of hospitalized cases. Figure 1 shows the
overall annual trends in malaria cases and deaths. The two
databases were analysed separately.
3.1. ImportedMalariaHospitalizations at NHSHospitals (DRG
Database). From 2000 to 2009, there were 2003 hospitaliza-
tions with malaria diagnosis, the annual incidence declining
from 314 hospitalizations in 2000 to 130 in 2009. Most cases
were male (1416, 71%) aged 18–64 years (1650, 82.4%, mean
age 37.7 years), with residence at Lisbon (986, 49.2%), Setubal
(169, 8.4%), and Porto (259, 12.9%). In-hospital mean length
of stay (LOS) was 8.09 days and lethality was 1.95% (39/2003).
In the first four years the annual number of malaria
hospitalizations was significantly higher than in the following
years (chi-square test 𝑃 < 0.001). Mean length of stay
remained stable throughout the years, varying from 6.88 days
to 9.39 days, the annual variation not being significantly
different (ANOVA test 𝑃 > 0.05). Lethality remained
relatively stable, ranging from 0.75% to 3.85%, with peaks in
2001 (2.5%), 2007 (3.3%), and 2009 (3.5%). Those who died
had a significantly higher mean length of stay (20.5 days for
those who died and 7.84 days for those who did not die, 𝑡-test,
𝑃 < 0.001).
In January, May, June, and December (202, 193, 207, and
203 cases resp.), observed cases exceeded by 26 to 40 those
expected. On the contrary, in February and March (132 and
126) the frequency of cases was 35 and 40 lower than expected
(chi-square test 𝑃 < 0.001). Mean length of stay ranged from
6.77 days in September to 9.32 days in April but no significant
differences were observed (ANOVA 𝑃 > 0.05). Absolute
mortality and lethality were the highest in March (𝑛 = 5,
3.97%) and the lowest in September (𝑛 = 1, 0.64%).
On age analysis, more than 75–80% of annual hospitaliza-
tions were on those aged 18–64 years. Older age (>64 years
old) corresponded to 5.9% (119) of all hospitalizations and
younger age (<18 years old) corresponded to 11.7% (234).
Older age (>64 years old) had significantly higher mean
length of stay (11.45 days versus 7.88 days, t-test, 𝑃 = 0.001)
and lethality (10% versus 1.43%, Fisher’s exact test,𝑃 < 0.001).
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Table 2: Prevalence and length of stay considering predefined comorbidities, on univariate and multivariate analysis.
Variables Prevalence Mean LOS Log LOS Log LOS
𝑁 (%) Days 𝑃 Unadjusted—RR (CI) 𝑃 Adjusted—RR (CI) 𝑃
Female gender 587 (29%) 8.15 versus 8.07 0.875 0.985 (0.908–1.068) 0.71 0.956 (0.886–1.031) 0.242
Age > 64 (LOS)
Age (log LOS) 119 (5.94) 11.2 versus 7.88 0.001 1.005 (1.003–1.007) <0.001 1.296 (1.116–1.504) 0.001
Malaria related to
pregnancy 37 (1.84) 8.41 versus 8.08 0.85 1.049 (0.797–1.381) 0.732
HIV infection 50 (2.50) 18.4 versus 7.83 <0.001 2.293 (1.813–2.898) <0.001 1.123 (0.859–1.470) 0.395
Other infections 145 (7.24) 17.93 versus 7.32 <0.001 2.214 (1.927–2.542) <0.001 1.853 (1.576–2.181) <0.001
Pneumonia 78 (3.89) 18.3 versus 7.6 <0.001 2.477 (2.054–2.986) <0.001 1.824 (1.507–2.210) <0.001
Respiratory failure 89 (4.44) 19 versus 7.6 <0.001 2.284 (1.916–2.724) <0.001 1.464 (1.212–1.770) <0.001
Chronic obstructive
pulmonary disease 35 (1.75) 12.66 versus 8.01 0.012 1.464 (1.104–1.941) 0.008 1.213 (0.931–1.578) 0.151
Diabetes mellitus 92 (4.60) 9.23 versus 8.04 0.304 1.293 (1.083–1.542) 0.004 1.108 (0.936–1.313) 0.232
Arterial hypertension 139 (6.94) 9.17 versus 8.01 0.226 1.184 (1.024–1.370) 0.023 1.054 (0.918–1.212) 0.457
Renal failure 90 (4.50) 16.1 versus 7.7 <0.001 1.759 (1.474–2.100) <0.001 1.176 (0.985–1.405) 0.090
Anemia 426 (21.27) 11.8 versus 7.09 <0.001 1.592 (1.458–1.738) <0.001 1.473 (1.353–1.603) <0.001














































Figure 2: Overall effect of age (age category in years) on case
frequency,mean length of stay (LOS), and lethality (DRGdata 2000–
2009).
Overall, malaria lethality increased steadily with increasing
age (0.9% <18, 1.5% 10–64, 10% >64) (Figure 2). On gender
analysis, themajority of annual hospitalizationswere inmales
and no significant differences were obtained for mean length
of stay (8.07 for male versus 8.15 for female, 𝑡-test, 𝑃 > 0.05)
nor for lethality (2.0% for male versus 1.7% for female, chi-
square test, 𝑃 > 0.05).
3.2. Imported Malaria Notifications of Hospitalized Cases
(Statutory Notification). Between 2000 and 2009, there were
541 confirmed malaria statutory notifications (480 hospital-
ized cases, 42 ambulatory cases, and 19 not known). From the
480 notifications referring to hospitalized cases, most were
in males (376, 78.3%), mean age was 38.5 years, and in 16
cases outcome was death (3.33%). Within these (𝑛 = 480),
P. falciparum was the most frequent agent of infection (𝑛 =
328, 68.3%) followed by P. vivax (𝑛 = 40, 8.3%). In 103 cases
(21.5%) there was no species identification. Eight coinfections
were identified: 5 with P. falciparum and P. vivax, 1 with P.
falciparum and P. ovale, and 2 with P. vivax and P. ovale. Nine
out of the 16 malaria deaths were due to P. falciparum and for
the remaining deaths the species was not specified. In 73.3%
of cases (𝑛 = 352) the identified origin of infection was sub-
Saharan Africa.
3.3. Factors Influencing Length of Stay and Mortality (Tables
2 and 3). Considering NHS malaria hospitalizations (𝑛 =
2003), the frequency of predefined comorbidities (age > 64,
pregnancy related malaria, HIV infection, other infections
excluding malaria, pneumonia, respiratory failure, chronic
obstructive lung disease, diabetes, arterial hypertension, renal
failure, anemia, and thrombocytopenia) ranged from 1.84%
(malaria related to pregnancy) to 21.27% (anemia).
3.3.1. Length of Stay (LOS). The overall in-hospital mean
length of stay was 8.09 days and the median was 6 (IQR
4–8). On univariate analysis, the following variables were
associated with prolonged length of stay: age > 64 years,
HIV infection, other infections, chronic obstructive lung
disease, pneumonia, respiratory failure, renal failure, and
anemia. Gender, diabetes, and arterial hypertension did not
significantly increase mean of length of stay. This association
prevailed on multivariate analysis for age, other infections,
pneumonia, respiratory failure, and anemia. Compared to
those without infection the adjusted relative ratio (RR) for
other infections was 1.85 (95% CI 1.57–2.18) followed by
pneumonia (RR = 1.82, 95% CI 1.51–2.21). Respiratory failure
has a high RR in unadjusted and adjusted analysis, although
it reduces after adjusting for possible confounding factors.
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Table 3: Prevalence and lethality considering predefined comorbidities, on univariate and multivariate analysis.
Variables Prevalence Lethality
𝑁 (%) 𝑁 (%) OR unadjusted (CI) 𝑃 OR adjusted (CI) 𝑃
Female gender 587 (29%) 9 (1.7%) 0.829 (0.401–1.712) 0.612 0.993 (0.410–2.403) 0.987
Age > 64 119 (5.94) 12 (10) 7.713 (3.802–15.648) <0.001† 5.374 (2.139–13.498) <0.001
Malaria related to pregnancy 37 (1.84) 2 (5.4) 2.979 (0.691–12.849) 0.161†
HIV infection 50 (2.50) 3 (6) 3.399 (1.011–11.430) 0.071† 2.766 (0.477–16.030) 0.256
Other infections 145 (7.24) 10 (6.9) 4.672 (2.230–9.789) <0.001† 2.543 (0.852–7.591) 0.094
Pneumonia 78 (3.89) 9 (11.5) 8.239 (3.767–18.022) <0.001† 1.035 (0.373–2.872) 0.947
Respiratory failure 89 (4.44) 26 (29) 60.349 (29.626–122.935) <0.001† 32.794 (13.163–81.703) <0.001
Chronic obstructive pulmonary disease 35 (1.75) 0 (0) — — — —
Diabetes mellitus 92 (4.60) 6 (6.5) 3.970 (1.620–9.730) 0.008† 2.103 (0.661–6.694) 0.208
Arterial hypertension 139 (6.94) 5 (3.6) 2.008 (0.773–5.219) 0.188†
Renal failure 90 (4.50) 17 (18.9) 20.017 (10.195–39.302) 0.001† 3.590 (1.471–8.759) 0.005
Anemia 426 (21.27) 11 (2.6) 1.466 (0.724–2.970) 0.285
Thrombocytopenia 374 (18.67) 8 (2.1) 1.127 (0.514–2.471) 0.766
†Fisher exact test due to small expected values.
On the contrary, age > 64 further increased length of stay
when other factors were considered together.
3.3.2. Lethality. The overall in-hospital lethality was 1.95%
(39/2003). On univariate analysis, the following variables
were associated with increased lethality: age > 64 years, HIV
infection, other infections, diabetes, pneumonia, respiratory
failure, and renal failure. This association prevailed on mul-
tivariate regression analysis for age > 64, respiratory failure,
and renal failure. In comparison to those without respiratory
failure the adjusted odds ratio was 32.79 (95%CI 13.16–81.70),
followed by age> 64 years (OR= 5.37, 95%CI 2.14–13.50).The
OR of the significant comorbidities decreased when the other
factors were considered together.
4. Discussion
Between 2000 and 2009, there were 2003 malaria admissions
to NHS hospitals in Portugal. The data show a consistent
declining annual trend contrasting with a relative stability in
mean length of stay and lethality observed in the same period.
Overall in-hospital lethality was 1.95% and mean length of
stay was 8.09 days.
This decreasing incidence of imported malaria despite
increasing global international travel (malaria endemic
regions included) is in contrast with the steady increase until
the year 2000 and has been observed in other countries in
Europe [4, 14, 15]. Reductions on malaria transmission have
been achieved inmanymalaria endemic countries, asmalaria
control programmes have been successfully implemented [16,
17]. Nevertheless, malaria hospitalizations are known to have
increased since 2009 in Portugal, increased expatriation to
malaria endemic countries being one plausible explanation
[18].
For the same time period (2000–2009), National Statu-
tory malaria notification consisting mainly of hospitalized
cases (480, 88.7% of total malaria notifications) only captured
a quarter of total hospitalizations and indicated stable annual
case frequency (40–50 per year), contradicting the declining
trend observed for NHS hospitalizations. This denotes very
high malaria underreporting, moreover considering that
many malaria cases are treated without hospital stay and
therefore are not included in the DRG database.
Malaria underreporting is not new but is worrying.
Underreporting estimates of imported malaria in Europe
ranged from 20 to 59% [19]. In Portugal there are no
quantified estimates. Malaria is included in the National
Notifiable Infectious Diseases Surveillance Programme, a
passive clinician based mandatory surveillance system. The
notification process is not very user friendly and the time
involved in completing the different steps in the system com-
promises timeliness. It consists ofmanually filling in a specific
notification paper form, common for all notifiable infectious
diseases, and parasite confirmation is microscopic and/or by
antigen detection test [1, 11]. There is no laboratory based
notification, contrary to other European countries which
have better reporting performances or improved them on
including such notification [1, 20–23]. The notification paper
forms are frequently not readily available in the institutions
and have to be sent by post. As such, with the daily hustle
bustle demands of patient care, clinicians may easily forget to
do it, furthermore considering they might not be fully aware
that malaria is included in the notifiable disease list or of the
legal requirement to report. The use of a notification paper
form, common to all notifiable infectious diseases, results in
missing or omission of relevant epidemiological data specific
to malaria. This is further aggravated by the fact that subse-
quent epidemiologic surveys ofmalaria cases and contacts are
not routinely done. Therefore, relevant information such as
time delay to diagnosis and treatment, duration and purpose
of travel, drug treatment used, and personal protection
measures is very difficult to gather. Contributing factors to
underreporting have not been analysed in Portugal but excess
work and lack of time, lack of familiarity with the list of
notifiable diseases, lack of understanding of the importance
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of notification, and concerns regarding confidentiality have
been identified elsewhere and can easily apply to Portugal
[24, 25]. This study confirms that malaria underreporting
is an issue and it needs to be thoroughly addressed to
uncover its reasons and implement strategies to overcome it.
Reporting timeliness delays, data quality and completeness of
data, cumbersome reporting process, and lack of laboratorial
notification, as discussed above, are other limitations to
consider in addition to the scarcity of systematic malaria
surveillance activities evaluation. Electronic Internet based
reporting systems are considered more efficient with proven
benefits in terms of timeliness and completeness compared to
conventional systems and are already in use in some countries
[26–28]. In Portugal, the implementation of the National
Epidemiology Surveillance System, an electronic national
surveillance system including infectious diseases and other
public health risks, is starting and improvements in reporting
performance are expected [29].
Cases showed a bimodal pattern with peaks in May-
June and December-January not combined with mortality
peaks. Sub-Saharan Africa was the main origin of imported
infection in Portugal as observed in this and others studies
[5, 6, 8].
Most cases occurred in working age male adults, a gender
and age predominance observed in other European and non-
European countries [3, 15, 30–32]. No male predominance
was observed for length of stay or lethality though. Increasing
age was strongly and independently associated with higher
length of stay [adjusted-RR for age 1.29 (CI 1.12–1.50, 𝑃 =
0.001)] and lethality [adjusted OR for age > 64 5.37 (CI 2.14–
13.50, 𝑃 < 0.001)]. These data are supported by previous
reports of increased lethality of importedmalaria in older age
groups [33–35].
Statutory notification identified falciparum malaria as
the most frequent agent of infection which is in agreement
with sub-Saharan Africa as the most common geographical
origin of infection. In 103 and 98 notifications, respectively,
the agent and origin of infection were not stated, reflecting
either reporting inaccuracies due to incomplete information
or inability for specific or complete species identification in
some hospitals, the latter due to the type of parasite detection
method used.
Inpatient malaria diagnosis and treatment policy in
Portugal follows WHO guidelines for malaria treatment,
but drug treatment consists firstly of quinine plus doxy-
cycline or quinine plus clindamycin [36]. IV artesunate
or artemisinin-based combination therapies (ACT) are not
widely available in hospitals but possible on request. Pri-
maquine is used on vivax infections. ACT combinations,
namely, dihydroartemisinin-piperaquine, are available for
outpatient treatment. Mefloquine and atovaquone/proguanil
are usually reserved for chemoprophylaxis [37].
Respiratory failure, renal failure, and severe anemia are
among the WHO criteria for severe malaria, predicting
higher risk of severe disease and death [38]. On comorbid-
ity analysis respiratory failure was associated with higher
length of stay and lethality, and renal failure was associated
with higher lethality but not higher length of stay. Anemia
increased length of stay but did not increase lethality. The
data however do not allow a severity stratified analysis as
other WHO criteria for severity could not be retrieved from
DRG database. Pneumonia and other infections significantly
increased length of stay but not lethality. Coinfections,
namely, pneumonia and bacteraemia, community acquired
or nosocomial, are not infrequent in hospitalized malaria,
especially in severe cases, and may affect management and
outcome [8, 39].
None of the chronic diseases analysed (HIV infection,
chronic pulmonary disease, diabetes mellitus, and arterial
hypertension) seemed to have an effect neither on length of
stay nor on lethality, their prevalence ranging from 1.75%
to 6.94%. The data on chronic diseases, such as diabetes
mellitus and arterial hypertension, and on the severity of
imported malaria are scarce. Their frequency does increase
with increasing age though, and age is an independent risk
factor for mortality as shown here and elsewhere [33–35].
Generally, the association of HIV infection and imported
malaria has not consistently been related to worse outcome,
its impact on malaria severity depending on the severity of
the immunosuppression [40–43].
Malaria outcome depends on many factors, as retrieved
from sentinel surveillance data, hospital based case series
(hospital clinical records), and surveillance data analysis
in countries with organized malaria surveillance programs.
These include nationality, traveler characteristics (e.g., expa-
triate, immigrant, VFR, etc.), geographic origin, travel des-
tination, adhesion to chemoprophylaxis, delays in seeking
medical care, delays in diagnosis and treatment of suspected
malaria, and treatment schedule that could not be included
in multifactorial analysis because they are not included in
the database [33, 44]. The results obtained however suggest
that some comorbidities may prolong the length of stay and
increase lethality.
There are limitations associated with the use of DRG
data. The information on hospital characteristics was not
gathered for epidemiological purposes; some vital features of
malaria patients are missing and therefore it does not allow
for the analysis of variables usually seen in epidemiologic
studies. The DRG data cannot account for multiple admis-
sions, reducing our experimental unit to discharge episode
instead of patient. Its use however allows for obtaining timely
nationwide data without the constraints and limitations of
surveillance systems, such as under diagnosis or underre-
porting, providing data that would be otherwise unfeasible or
logistically, cumbersome, difficult, and expensive to obtain.
Malaria is not easily subject to miscoding, due to diag-
nosis specificities (parasite detection by microscopy, anti-
gen detection tests, or molecular PCR technology), though
malaria subtypes may not be accurately or specifically
discriminated on codification; therefore no such subtype
analysis was done within the DRG database.
The use of hospital episode statistics, such as DGR
database, for research and epidemiological purposes in infec-
tious and noninfectious diseases, being able to congregate
data at local and national level, is not original though results
have to be analyzed considering the specificities of the
disease under study, data quality and coding accuracy, and
advantages and limitations of the database [45].
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5. Conclusions
This is to our knowledge the first comprehensive national
level study on imported malaria in Portugal and one that
provides new insight on malaria burden estimates, partic-
ularly concerning malaria treated in hospitals, using the
national databases available. Hospitalized malaria notifica-
tions reflected a quarter of NHS malaria hospitalizations and
less than half of in-hospital lethality. Older age significantly
increased hospital stay and lethality, and comorbidities are
suggested as significant influencing factors. P. falciparumwas
the main plasmodium species responsible for the malaria
cases and sub-Saharan Africa is the main geographic region
of infection.
Along with climate change, international travel is thought
to increase the risk of imported malaria, making malaria
surveillance an important pillar of public health protection.
Hospital statistics episodes (DRG database) analysis may
be an unexplored complementary resource, in addition to
statutory notification, for imported malaria surveillance in
Portugal, especially considering the nonquantified underre-
porting, the increasing international travel, and the recent
boost in emigration to malaria endemic regions in Portugal.
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